Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
Keyword(s):
Phase I
◽
2011 ◽
Vol 18
(4)
◽
pp. 1092-1100
◽
2009 ◽
Vol 15
(7)
◽
pp. 2552-2558
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 3016-3016
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 2530-2530
◽
2011 ◽
Vol 29
(15_suppl)
◽
pp. 3098-3098
◽